Clinical trials: PPA
Alzheimer Disease, Early Onset, Alzheimer Disease
Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks
This study attempts to identify two types of AD by using clinical and cognitive tasks and brain imaging. The subtypes of AD are separated into a "typical" group (memory loss) and a "variant" group (language, visuospatial, and…
- Conditions
- Alzheimer Disease, Early Onset, Alzheimer Disease, Alzheimer Disease, Late Onset, Dementia, Alzheimer Type
- Trial name
- EOAD-Subtype (NCT03153371)
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Opioid-Related Disorders
Tau PET Imaging in Opioid Use Disorder
The investigators plan to enroll up to 60 adult subjects in this study. There will be three groups of up to 20 subjects each in this study.
- Trial name
- NCT05651516
- Testing
- 18F-PI-2620 PET/CT
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Cognition, Affect (Mental Function)
ETASCAI Pilot Project
This pilot study aims to investigate the chronic effects of ETAS® on cognitive, affective and inflammatory outcomes in healthy adults aged 60-80 years with mild to moderate subjective cognitive complaints.
- Conditions
- Cognition, Affect (Mental Function), Inflammation
- Trial name
- NCT06790849
- Testing
- Active 1 ETAS®, Active 2 ETAS®
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Reading
Cough
Codeine Phosphate/Guaifenesin ER Tablet 30 mg/600 mg Steady State Clinical Study
The objectives of this pivotal study are: 1. to evaluate bioavailability of an extended-release and immediate release Codeine Phosphate/Guaifenesin tablet at steady state following multiple oral administration 2.
- Trial name
- COGUSS (NCT02572375)
- Testing
- Codeine Phosphate/Guaifenesin ER Tablet, Codeine Phosphate/Guaifenesin IR Tablet
- Where
- Jordan
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Nexgen Pharma, Inc
Fabry Disease, Gaucher Disease
Complement Activation in the Lysosomal Storage Disorders
The lysosomal storage disorders (LSDs) are monogenic disorders associated with inflammation affecting multiple organs, and early death.
- Conditions
- Fabry Disease, Gaucher Disease, Niemann-Pick Disease, Type C, Lysosomal Storage Diseases
- Trial name
- CATALYST (NCT04189601)
- Testing
- Complement measurements
- Where
- Australia
- Volunteers
- healthy volunteers welcome
- Sponsor
- Melbourne Health
Apathy, Behavior
Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.
The purpose of this study is to provide relevant quantitative evaluation of apathy close to real life situation by means of a multimodal sensor system integrated.
- Conditions
- Apathy, Behavior, Frontotemporal Dementia
- Trial name
- ECOCAPTURE (NCT02496312)
- Testing
- Evaluation of Apathy Close to Real Life Situation
- Where
- France
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Alzheimer's Disease Diagnosis
Modelling Tau Distribution From DTI With Generative Adversarial Network for Alzheimer's Disease Diagnosis
The most significant impact of this project is to propose for the first time a novel generative adversarial network (GAN), as one kind of deep learning architecture, to automatically generate synthetic PET images reflecting tau…
- Trial name
- NCT05020626
- Where
- Hong Kong
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Primary Progressive Aphasia, Semantic Dementia
Treatment for Speech and Language in Primary Progressive Aphasia
Primary progressive aphasia (PPA) is a progressive neurological disorder that causes a gradual decline in communication ability as a result of selective neurodegeneration of speech and language networks in the brain.
- Conditions
- Primary Progressive Aphasia, Semantic Dementia, Semantic Memory Disorder, Logopenic Progressive Aphasia
- Trial name
- NCT04881617
- Testing
- Lexical Retrieval Training (LRT), Video-Implemented Script Training for Aphasia (VISTA)
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Texas at Austin
Alzheimer Disease, Lewy Body Dementia (LBD)
The Role of Advanced Electroencephalographic Data as Marker of Pathology and Prognosis in Primary Dementias
The study aims to use advanced brainwave recordings of electroencephalogram (EEG) to understand early signs of Alzheimer's disease (AD) in people with mild memory problems, known as amnestic Mild Cognitive Impairment (MCI).
- Conditions
- Alzheimer Disease, Lewy Body Dementia (LBD), Mild Alzheimer Disease, Frontotemporal Dementia (FTD)
- Trial name
- NCT06826157
- Testing
- Electroencephalogram, 3 Tesla MRI, Apolipoprotein E genetic test
- Where
- Italy
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Memory Disorders, Alzheimer Disease
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
The proposed study is designed to evaluate the performance of the COGNISION™ System as a tool to assist physicians in diagnosing Alzheimer's Disease (AD) in real-world clinical settings.
- Conditions
- Memory Disorders, Alzheimer Disease, Dementia, Cognitive Impairment
- Trial name
- COGNISION™ (NCT00938665)
- Testing
- COGNISION™ System
- Where
- 7 sites in United States
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Neuronetrix, Inc.
FTD, AD
Metabolic Characterization of Alzheimer's Disease and Frontotemporal Dementia by 23Na-MRI and FDG-PET
Alzheimer's disease (AD) and frontotemporal dementia (FTD) are the most common forms of neurodegenerative dementia. However, their differential and timely diagnosis can be challenging for clinicians, therefore often closing the…
- Conditions
- FTD, AD, Healthy Controls
- Trial name
- MetaAD_FTD (NCT07100470)
- Testing
- Sodium MRI
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier St Anne
Mild Cognitive Impairment, Alzheimer Disease
Alzheimer's Disease Neuroimaging Initiative 4
The Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4) is a non-randomized, longitudinal, natural history study designed to validate biomarkers, improve clinical trial design, and advance understanding of Alzheimer's disease…
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Dementia
- Trial name
- ADNI4 (NCT05617014)
- Testing
- Neuraceq, Amyvid, Tauvid
- Where
- 65 sites in United States, Canada
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- University of Southern California